BioSpace News Archive

Business

SYGNIS AG Reports Financial Results for the Third Quarter and First Nine Months of 2017

Revenues increased 4-fold to € 5.3M for the first nine months of 2017 through a combination of organic and acquisitive growth.

November 8, 2017

·

8 min read

Business

Cambrex Invests in New Small Scale Capacity at Its Charles City, Iowa Facility

The project has seen the installation of two 500 gallon glass lined reactors and creates a third small scale work center, further increasing flexibility for customer projects.

November 8, 2017

·

2 min read

Business

Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017

Lipocine reported a net loss of $4.7 million, or ($0.22) per diluted share, for the third quarter ended September 30, 2017.

November 8, 2017

·

8 min read

Business

Amylon Therapeutics Targeting Central Nervous System Disorders Wins Startup Slam Competition at BIO-Europe Berlin

Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europe Spring 2018 from EBD Group and the opportunity to enter a year-long no fee arrangement to become a J&J Innovation, JLINX community member.

November 8, 2017

·

2 min read

Business

Skyline Medical Announces Two Proposed Joint Ventures and New Strategic Focus on CRO Services

New collaborations with Helomics and CytoBioscience to diversify Skyline’s operations into the rapidly growing CRO Services sector.

November 8, 2017

·

8 min read

Genetown

SeraCare Announces Industry’s First Comprehensive NGS Reference Material for Hematologic Malignancies

To help clinical labs performing NGS-based myeloid testing thoroughly understand and characterize their assays, SeraCare has developed the Seraseq Myeloid Mutation DNA Mix and Seraseq Myeloid Fusion RNA Mix.

November 8, 2017

·

4 min read

Cannabics Pharma Files Patent Application on Cannabinoid Modulation of the Microbiome

Cannabics Pharma announced today that it has filed the first of a cluster of patent applications with the USPTO which covers their ongoing work on the use of cannabinoid products for adjusting the varied microbial populations that live on and in the body.

November 8, 2017

·

3 min read

Drug Development

iVeena Delivery Systems Completes Phase I/IIa Pilot Clinical Study of IVMED-10 for Post-Cataract Inflammation

iVeena has additional clinical studies of IVMED-10 and initial studies of IVMED-20 planned for Q1 2018.

November 8, 2017

·

2 min read

Pharm Country

Mitochon Pharmaceuticals Announces First Patent Allowance for Mitochondrial Targeted Therapies for Neurodegeneration

This patent allowance will help secure the path forward for the continued clinical development of MP101 in: Huntington’s Disease, Optic neuritis and Duchenne’s Muscular Dystrophy.

November 8, 2017

·

2 min read

Horama Raises €19 Million in a Series B Financing Round

This fundraising was intended to finance the development of the HORA-PDE6B project, including the start of its clinical phase, which has just been authorised by the French regulatory bodies.

November 8, 2017

·

6 min read